drugset / Trial / NCT01372202
CHFR Methylation Status Esophageal Cancer Study
Phase 2
Terminated
31 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 Study of Paclitaxel with Cisplatin versus Fluoropyrimidine with a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-06
- Completion
- 2014-10-01
Outcome
Outcome not reported
Stopped: “Study stopped due to early stopping rule”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 30 mg/m2 | — |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 50 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 180 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 1000 mg/m2 | — |